Midazolam ODT is under clinical development by Melt Pharmaceuticals and currently in Phase I for Sedation. According to GlobalData, Phase I drugs for Sedation have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Midazolam ODT’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Midazolam ODT overview
Midazolam (MELT-210) is under development for procedural sedation. The drug candidate is administered through sublingual route in the form of orally disintegrating tablet (ODT). It acts by targeting gamma-aminobutyric acid type A receptor subunit (GABA(A) receptor or GABR).
Melt Pharmaceuticals overview
Melt Pharmaceuticals is dedicated to the development of innovative approaches to procedural sedation and analgesia for short-term medical operations. The company is headquartered in United States.
For a complete picture of Midazolam ODT’s drug-specific PTSR and LoA scores, buy the report here.